Comparative Pharmacology
Head-to-head clinical analysis: HISPRIL versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISPRIL versus X TROZINE L A.
HISPRIL vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISPRIL (lisinopril) is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and afterload.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
10 mg orally once daily, increased to 20 mg once daily after 2-4 weeks if needed.
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
The terminal elimination half-life of HISPRIL is approximately 12-15 hours in patients with normal renal function, supporting twice-daily dosing. In moderate to severe renal impairment (CrCl <30 mL/min), half-life is prolonged up to 30-40 hours, necessitating dose interval adjustment.
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
HISPRIL is predominantly excreted renally, with approximately 60-70% of an administered dose recovered unchanged in urine over 48 hours. Hepatic metabolism accounts for <10% of elimination, and fecal excretion contributes <5%.
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category C
Category C
Antihistamine
Antihistamine